Selection of the Optimal L-asparaginase II Against Acute Lymphoblastic Leukemia: An In Silico Approach.

ABSTRACT:

Background

L-asparaginase II (asnB), a periplasmic protein commercially extracted from E coli and Erwinia, is often used to treat acute lymphoblastic leukemia. L-asparaginase is an enzyme that converts L-asparagine to aspartic acid and ammonia. Cancer cells are dependent on asparagine from other sources for growth, and when these cells are deprived of asparagine by the action of the enzyme, the cancer cells selectively die.

Objective

Questions remain as to whether asnB from E coli and Erwinia is the best asparaginase as they have many side effects. asnBs with the lowest Michaelis constant (Km; most potent) and lowest immunogenicity are considered the most optimal enzymes. In this paper, we have attempted the development of a method to screen for optimal enzymes that are bett

SUBMITTER: Baral A 

PROVIDER: S-EPMC10414282 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature